The core of FMEA risk calculation rests on three pillars: Occurrence, Severity, and Detection.
In clinical laboratory and diagnostic testing, risk is quantified by evaluating how often a failure might happen (occurrence), how severe its impact would be on patient care (severity), and how likely current quality controls are to catch it before results are released (detection). These components, when combined, produce a structured risk profile that prioritizes where to direct preventive resources.
FMEA translates qualitative fears about diagnostic errors into a data-driven ranking. By scoring occurrence, severity, and detection on a consistent scale and viewing them together—often as a Risk Priority Number (RPN)—you can move from guessing which vulnerabilities matter most to knowing.
The Three Pillars of FMEA in Laboratory Medicine
Occurrence: How Likely Is the Failure?
Occurrence describes the probability that a specific failure mode will happen during routine workflow.
In laboratory terms, this might mean a reagent lot-to-lot shift, a pipetting error in specimen handling, or an instrument drift beyond acceptable limits.
The rating is typically on a 1–10 scale, where 1 reflects a virtually impossible event and 10 a near-certain or frequent occurrence.
Using historical data, reagent stability studies, and operator competency records helps populate this rating objectively.
Severity: What Is the Clinical Consequence If It Happens?
Severity captures the magnitude of harm or impact the failure would impose on the patient or diagnostic decision-making.
A failure that leads to a missed critical value like troponin carries catastrophic severity; a failure that causes a slight delay with no clinical impact ranks low.
Even when occurrence is low, a high severity score demands attention.
In clinical workflows, severity often overrides other factors because patient safety is the over-arching priority.
Detection: Will Our Current Controls Catch It in Time?
Detection reflects the probability that existing quality controls, algorithms, or review steps will identify the failure before the result is reported.
It is not about whether the failure can be detected eventually, but whether the current safeguards will catch it before it reaches the clinician.
A robust system—featuring internal controls, sample adequacy checks, delta flags, and automated rerun rules—earns a low detection score (meaning high detectability).
A failure that slides silently through all checks, like an interferent that passes the sample check, receives a high detection score, signaling a dangerous blind spot.
From Components to a Prioritized Score
The classic Risk Priority Number (RPN) multiplies the three scores:
RPN = Occurrence × Severity × Detection
The result is a number ranging from 1 to 1000 that highlights which failure modes demand immediate corrective action.
However, clinical laboratories often adapt this calculation.
Some adopt a two-factor risk model (occurrence × severity) and use a risk acceptability matrix to categorize risks into low/tolerable, moderate, or high/unacceptable zones—removing detection when failures can cause harm before any control can intervene.
Understanding the Trade-offs and Limitations
The Subjectivity of the 1–10 Scale
While the scales bring structure, they rely on the team’s judgment, which can vary.
Inconsistent scoring—especially between different departments or during early assay development—can lead to misprioritized risks.
Using well-defined, laboratory-specific rating tables for each component helps reduce this variability, but never eliminates it entirely.
The Detection Paradox in Clinical Settings
Detection scores are only useful when a control can realistically intercept the failure before the result is reported.
For instance, if a specimen is hemolyzed and the interference causes an immediate inaccurate result, post-analytical review fails to detect it in time.
In such cases, a low detection score (good detectability) can create a false sense of security if the control point occurs too late in the workflow. This is why many clinical FMEA frameworks warn against over-reliance on detection and may revert to a two-factor (occurrence × severity) evaluation.
The Silencing Effect of Multiplication
Multiplying three numbers can mask extreme risks.
A failure with Severity = 10 (catastrophic) and Detection = 10 (no control catches it) might still yield a mid-range RPN if Occurrence is rated a 2.
A strict RPN ranking could deprioritize this “low-probability, high-impact” event—something healthcare risk managers often override using a risk matrix that highlights any combination of high severity and poor detectability regardless of total RPN.
Making the Right Choice for Your Workflow
The best FMEA framework is the one that mirrors your clinical reality and regulatory obligations. Use the following guide to align your approach with your lab’s primary goal.
- If your primary focus is ISO 14971 or CLSI EP23 compliance: Build your risk analysis on a three-factor RPN model that includes detection, but supplement it with a risk acceptability matrix to catch high-severity events that may rank deceptively low.
- If your primary focus is pre-market IVD assay development: Concentrate on reducing occurrence and improving detection through robust raw material selection, rigorous method validation, and strategic control placement. A detection-weighted RPN helps you prove to regulators that your assay self-monitors effectively.
- If your primary focus is clinical laboratory daily operations with immediate patient impact: Consider a two-factor (occurrence × severity) matrix to quickly identify failure modes where harm cannot be reversed by detection, and target those with immediate corrective SOPs.
- If your primary focus is balancing resources across hundreds of potential failure modes: Start with an RPN screening, then re-evaluate any failure mode with Severity ≥ 8 or Detection ≥ 8 manually, regardless of the composite score, to ensure no hidden catastrophic risks slip through.
Understanding the interplay of occurrence, severity, and detection transforms risk management from a regulatory checkbox into a practical, patient-centered safety tool.
Summary Table:
| FMEA Component | Definition in Clinical Diagnostics | Primary Focus / Scale | RPN Role |
|---|---|---|---|
| Occurrence (O) | Probability that a failure mode occurs during workflow | Reagent stability, instrument drift, operator error (1–10) | Identifies historical frequency |
| Severity (S) | Clinical impact or harm to patient care if failure occurs | Missed critical values, misdiagnosis severity (1–10) | Overriding patient safety metric |
| Detection (D) | Likelihood existing controls catch error before result release | Quality control rules, delta flags, auto-reruns (1–10) | Measures control effectiveness |
| RPN Calculation | Overall risk ranking (RPN = Occurrence × Severity × Detection) | Composite score ranging from 1 to 1000 | Prioritizes preventive resources |
Strengthen Your Diagnostic Workflows & IVD Quality Controls
Navigating FMEA risk management in clinical diagnostics demands high-performing assay components, robust controls, and reliable method validation. At CamelBio, we provide diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—supporting your team at every stage from concept to clinic.
Whether you need to minimize lot-to-lot occurrence risks, enhance detection capabilities, or meet ISO 14971 / CLSI EP23 compliance standards, CamelBio is your trusted partner.
Contact CamelBio today to optimize your diagnostic assays and risk management processes!